A Cleveland Clinic-led team of scientists and physicians have discovered that the immune checkpoint protein VISTA can directly turn off tumor-fighting T-cells during immunotherapy and resist treatment.
May 17, 2024
0
22
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic ...
Oct 22, 2023
0
1
With more than 200 types of cancer and every cancer individually unique, ongoing efforts to develop precision oncology treatments remain daunting. Most of the focus has been on developing genetic sequencing assays or analyses ...
Apr 18, 2024
0
50
Liver inflammation, a common side-effect of cancers elsewhere in the body, has long been associated with worse cancer outcomes and more recently associated with poor response to immunotherapy. Now, a team led by researchers ...
Apr 19, 2024
0
40
The Wistar Institute's David B. Weiner and collaborators have engineered novel monoclonal antibodies that engage natural killer (NK) cells through a unique surface receptor that activates the immune system to fight against ...
Nov 1, 2023
0
21
Scientists have made an unusual discovery that could help to identify patients who are up to two-and-a-half times more likely to respond to currently available cancer drugs.
Jan 29, 2024
0
91
For some leukemia patients, the only potential chemotherapy option is a drug that also carries a high risk of heart failure. This means that some patients who recover from their cancer will end up dying of heart disease brought ...
Feb 8, 2024
0
0
An Oregon Health & Science University-developed platform for cytomegalovirus-based vaccines shows promise as a "shield" against cancer. The findings were recently published in the journal Science Advances.
May 29, 2024
0
60
Researchers have revealed a new mechanism of targeted drug treatment used against chronic lymphocytic leukemia, through the promotion of immune cell function, that could be exploited using new anti-cancer immunotherapies.
Oct 19, 2023
0
0
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die. This new ability to ...
Oct 24, 2023
0
41
